These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16673608)

  • 21. [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
    Paparella S; Finkelberg E; Varisco D; Tondelli E; Rocco F
    Urologia; 2011; 78(4):300-4. PubMed ID: 22139807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer.
    Carter JA; Botteman MF
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):425-37. PubMed ID: 22540167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of bone metastases in prostate cancer: a review.
    Bienz M; Saad F
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zometa European Study (ZEUS): another failed crusade for the holy grail of prostate cancer bone metastases prevention?
    Tombal B
    Eur Urol; 2015 Mar; 67(3):492-4. PubMed ID: 24666840
    [No Abstract]   [Full Text] [Related]  

  • 26. NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours.
    Jilani A; Garrett Z; Sutcliffe F; Stevens A
    Lancet Oncol; 2012 Dec; 13(12):1194-5. PubMed ID: 23323278
    [No Abstract]   [Full Text] [Related]  

  • 27. Zoledronic acid in genitourinary cancer.
    Climent MA; Anido U; Méndez-Vidal MJ; Puente J
    Clin Transl Oncol; 2013 Nov; 15(11):871-8. PubMed ID: 23615978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The role of bisphosphonate in the treatment of bone metastases from prostate cancer].
    Sallami S; Ben Rhouma S; Cherif K; Benrais N; Horchani A
    Tunis Med; 2012 Jul; 90(7):507-11. PubMed ID: 22811222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of zoledromic acid on pain control in stages M1b of prostate cancer].
    Alvarez-Múgica M; Fernández Gómez JM; Jalón Monzón A; González Alvarez RC; García Rodríguez J; Martín Benito JL
    Actas Urol Esp; 2007; 31(10):1100-6. PubMed ID: 18314647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reply to F. Valcamonico et al.
    Smith MR; Halabi S; Small EJ
    J Clin Oncol; 2014 Nov; 32(32):3685. PubMed ID: 25225438
    [No Abstract]   [Full Text] [Related]  

  • 31. [Zoledronic acid and bone pathology in the course of neoplasia. Part I].
    Caffo O
    Tumori; 2005; 91(5):22-6. PubMed ID: 16459649
    [No Abstract]   [Full Text] [Related]  

  • 32. Annual zoledronic acid: is less more?
    Higano CS
    J Clin Oncol; 2007 Mar; 25(9):1026. PubMed ID: 17369565
    [No Abstract]   [Full Text] [Related]  

  • 33. Breast cancer bone metastases: denosumab or zoledronic acid?
    van der Pluijm G
    Nat Rev Endocrinol; 2011 Mar; 7(3):134-5. PubMed ID: 21343953
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration.
    Berruti A; Cook R; Saad F; Buttigliero C; Lipton A; Tampellini M; Lee KA; Coleman RE; Smith MR
    Oncologist; 2012; 17(5):645-52. PubMed ID: 22523198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
    Lein M; Wirth M; Miller K; Eickenberg HU; Weissbach L; Schmidt K; Haus U; Stephan C; Meissner S; Loening SA; Jung K
    Eur Urol; 2007 Nov; 52(5):1381-7. PubMed ID: 17321667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reply from authors re: Bertrand Tombal. Zometa European Study (ZEUS): another failed crusade for the holy grail of prostate cancer bone metastases prevention? Eur Urol 2015;67:492-4: ZEUS: the quest for the holy grail of prostate cancer bone metastases prevention continues.
    Witjes WP; Patel A; Wirth M
    Eur Urol; 2015 Mar; 67(3):494-5. PubMed ID: 24726855
    [No Abstract]   [Full Text] [Related]  

  • 37. [Encounter of cancer cells with bone. Management of bone metastasis arising from prostate cancer].
    Kamoto T
    Clin Calcium; 2011 Mar; 21(3):465-71. PubMed ID: 21358069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unravelling the role of denosumab in prostate cancer.
    Aragon-Ching JB
    Lancet; 2011 Mar; 377(9768):785-6. PubMed ID: 21353698
    [No Abstract]   [Full Text] [Related]  

  • 39. The use of zoledronic acid in pediatric cancer patients.
    August KJ; Dalton A; Katzenstein HM; George B; Olson TA; Wasilewski-Masker K; Rapkin LB
    Pediatr Blood Cancer; 2011 Apr; 56(4):610-4. PubMed ID: 21298747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    Saad F; Lipton A
    BJU Int; 2006 Jun; 97(6):1351-2. PubMed ID: 16686742
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.